These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC. J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745 [Abstract] [Full Text] [Related]
5. The Quest for a Universal Flu Vaccine: Headless HA 2.0. Krammer F. Cell Host Microbe; 2015 Oct 14; 18(4):395-7. PubMed ID: 26468743 [Abstract] [Full Text] [Related]
8. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Cho A, Wrammert J. Curr Opin Virol; 2016 Apr 14; 17():110-115. PubMed ID: 27031684 [Abstract] [Full Text] [Related]
10. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ. Science; 2010 Aug 27; 329(5995):1060-4. PubMed ID: 20647428 [Abstract] [Full Text] [Related]
11. Options and obstacles for designing a universal influenza vaccine. Jang YH, Seong BL. Viruses; 2014 Aug 18; 6(8):3159-80. PubMed ID: 25196381 [Abstract] [Full Text] [Related]
12. Progress in the Development of Universal Influenza Vaccines. Sun W, Luo T, Liu W, Li J. Viruses; 2020 Sep 17; 12(9):. PubMed ID: 32957468 [Abstract] [Full Text] [Related]
13. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets. Maltais AK, Stittelaar KJ, Veldhuis Kroeze EJ, van Amerongen G, Dijkshoorn ML, Krestin GP, Hinkula J, Arwidsson H, Lindberg A, Osterhaus AD. Vaccine; 2014 May 30; 32(26):3307-15. PubMed ID: 24690149 [Abstract] [Full Text] [Related]
14. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response. Lee JS, Chowdhury MY, Moon HJ, Choi YK, Talactac MR, Kim JH, Park ME, Son HY, Shin KS, Kim CJ. J Virol Methods; 2013 Dec 30; 194(1-2):280-8. PubMed ID: 24004822 [Abstract] [Full Text] [Related]
15. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. Settembre EC, Dormitzer PR, Rappuoli R. J Mol Cell Biol; 2011 Jun 30; 3(3):144-6. PubMed ID: 21430014 [Abstract] [Full Text] [Related]
16. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Krammer F. Biotechnol J; 2015 May 30; 10(5):690-701. PubMed ID: 25728134 [Abstract] [Full Text] [Related]
17. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Inn KS, Lee GJ, Quan FS. Immunol Invest; 2014 May 30; 43(3):236-54. PubMed ID: 24354853 [Abstract] [Full Text] [Related]
18. Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice. Liu Q, Xue C, Zheng J, Liu K, Wang Y, Wei Y, Liu GD, Cao Y. Vaccine; 2015 Jul 31; 33(32):4035-40. PubMed ID: 26100927 [Abstract] [Full Text] [Related]
19. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine. Wu Q, Xiao S, Fan H, Li Y, Xu J, Li Z, Lu W, Su X, Zou W, Jin M, Chen H, Fang L. Antiviral Res; 2011 Dec 31; 92(3):493-6. PubMed ID: 22020305 [Abstract] [Full Text] [Related]
20. Comparative analysis of antibody induction and protection against influenza virus infection by DNA immunization with HA, HAe, and HA1 in mice. Chen J, Liu Q, Chen Q, Xiong C, Yao Y, Wang H, Wang H, Chen Z. Arch Virol; 2014 Apr 31; 159(4):689-700. PubMed ID: 24132721 [Abstract] [Full Text] [Related] Page: [Next] [New Search]